Signatera™ for colorectal cancer: Knowing earlier can make a difference
…to know that is a test out there to
let you know your odds are low…
it allows you to go back to living.
Brooks Bell
patient
Discover our BESPOKE study of ctDNA-guided therapy for colorectal cancer
Do you want to be a part of something extraordinary? Join Natera’s BESPOKE CRC study to make a difference for individuals who, like you, have been diagnosed with colorectal cancer (CRC). The study will examine the use of Signatera and the impact it has on treatment decisions for clinical outcomes in patients with stage II and III colorectal cancer. The study will enroll at least one thousand patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled patients for two years. Participants may receive up to $150 dollars for their time.
Visit our Signatera BESPOKE study page to learn more about participating in the clinical study.
How is the Signatera test performed?
Personalized, tumor-informed assay
One-time, primary tissue sample and matched normal tissue is required for whole exome sequencing and personalized test design.
Ultrasensitive ctDNA detection
Signatera is designed to detect ctDNA of somatic and truncal variants to optimize sensitivity. Tumor-informed method enables filtering of CHIP mutations to decrease false positive rates.
Optimized for longitudinal monitoring
Once the patient’s personalized test has been designed, only a blood sample is needed each subsequent time Signatera is ordered for the program or Surveillance program.
Shared decision making with Dr. John H.
Strickler, MD and patient Brooks
Patient Resources
